Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia

Blood

Volumn 99, Issue 10, 2002, Pages 3763-3770

  Van Der Kolk, Dorina M ^a,b,c,d   Vellenga, Edo ^a,b,c,d   Scheffer, George L ^a,b,c,d   Müller, Michael ^a,b,c,d   Bates, Susan E ^a,b,c,d   Scheper, Rik J ^a,b,c,d   De Vries, Elisabeth G E ^a,b,c,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD34 ANTIGEN; CYTOSTATIC AGENT; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037093101     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3763     Document Type: Article

References (41)

1. Cell biological mechanisms of multidrug resistance in tumor
2. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line
3. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport
4. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
5. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study
6. P-gp and MRP activities in relation to treatment outcome in acute myeloid leukemia
7. JC-1: A very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia
8. A multidrug resistance transporter from human MCF-7 breast cancer cells
9. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
10. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
11. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
12. Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: Role of c-myc and bcl-2 in apoptotic cell death
13. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
14. The multi-drug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
15. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C
16. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia
17. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
18. A doubleblind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031)
19. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study
20. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
21. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapse acute myeloid leukemia
22. BCRP is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines
23. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
24. The ABCG2 transporter is an efficient Hoechst-33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors
25. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype
26. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy: The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report
27. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia
28. Pharmacology of L-660,711 (MK-571): A novel potent and selective leukotriene D4 receptor antagonist
29. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells
30. Activity and expression of the multidrug resistance proteins-1MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells
31. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells
32. Increased expression of the novel drug resistance gene BCRP, but not of MDR1, LRP/MVP, and MRP1 in relapsed/refractory AML using real time quantitative RT-PCR (Taqman analysis)
33. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995)
34. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALBG9720)
35. Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: The impact on MRP activity
36. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane
37. Evidence that a cell-type-specific efflux pump regulates cell differentiation in Dictyostelium
38. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis
39. P-glycoprotein protects leukemia cells against caspasedependent, but not caspase-independent, cell death
40. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
41. Surface marker expression in acute myeloid leukemia at first relapse